&lt;p&gt;Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?&lt;/p&gt;

Kyriazoglou, Anastasios; Koutsoukos, Konstantinos; Zagouri, Flora; Liontos, Michalis; Dimitriadis, Efthimios; Tiniakos, Dina; Dimopoulos, Meletios A.

doi:10.2147/tcrm.s220804

Cited by 3 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Less commonly, the fusion found is YAP1-TFE3, detected by TFE3 immunoreactivity (4). While HEHE has been known as a slow-growing tumor of indolent nature (5)(6)(7), this is the first case report in which the tumor growth was measured, showing nodules that enlarged and spread to other organs in a given time span.…”

Section: Introductionmentioning

confidence: 81%

“…Less commonly, the fusion found is YAP1-TFE3, detected by TFE3 immunoreactivity ( 4 ). While HEHE has been known as a slow-growing tumor of indolent nature ( 5 - 7 ), this is the first case report in which the tumor growth was measured, showing nodules that enlarged and spread to other organs in a given time span. We present the following case in accordance with the CARE reporting checklist (available at https://tgh.amegroups.com/article/view/10.21037/tgh-22-48/rc ).…”

Section: Introductionmentioning

confidence: 84%

See 1 more Smart Citation

Hepatic epithelioid hemangioendothelioma: how fast does it grow and which findings could have prevented diagnostic delay?—a case report

Ribeiro¹,

Lemos²,

Moraes³

et al. 2023

Transl Gastroenterol Hepatol

View full text Add to dashboard Cite

Background: Hepatic epithelioid hemangioendothelioma (HEHE) is a rare neoplastic disease of varied presentation and unspecific radiological signs in the early stages. The diagnostic delay can lead to metastatic disease, thus increasing the tumor burden and reducing the treatment options. HEHE is usually deemed a slow-growing tumor, but its speed of growth is poorly reported and still unknown.Case Description: In this case report, we documented a HEHE diagnosed in a young woman who had complaints of abdominal pain, weight loss and bloating for a long time. The typical findings observed in histological studies were not promptly recognized in the histological analyzes, even after two laparoscopicguided liver biopsies, delaying the diagnosis until extrahepatic tumor spreading. Findings observed in computed tomography, magnetic resonance imaging and histological studies are presented. The coalescence of nodules and the rising of giant masses, occupying large parts of the liver in a specific time span, were registered and quantified. As opposed to prior reports, the results show that hepatic HEHE can grow rapidly, reinforcing the need of early diagnosis, thus avoiding the complications presented herein. Conclusions:The findings observed via radiological and histological imaging that could have avoided the diagnosis delay are depicted and discussed, showing that HEHE can rise faster than previously documented.

show abstract

Section: Introductionmentioning

confidence: 81%

Section: Introductionmentioning

confidence: 84%

Hepatic epithelioid hemangioendothelioma: how fast does it grow and which findings could have prevented diagnostic delay?—a case report

Ribeiro¹,

Lemos²,

Moraes³

et al. 2023

Transl Gastroenterol Hepatol

View full text Add to dashboard Cite

show abstract

“…[46][47][48][49][50][51] Recientemente se ha ensayado olaratumab más doxorrubicina en HEE hepático metastásico logrando una enfermedad estable. 52 Finalmente, Fukuhara et al 53 reportan un HEE hepático agresivo que ha sido tratado con trasplante hepático de forma exitosa.…”

Section: Discussionunclassified

Hemangioendotelioma cardiaco primario recurrente: reporte de caso y revisión de la literatura

Rosero¹,

Martínez²,

Gutiérrez³

et al. 2023

Rev.Col.Hematol.Oncol

View full text Add to dashboard Cite

El hemangioendotelioma epitelioide (HEE) es un tumor maligno posiblemente de origen vascular. Su localización usual es los tejidos blandos, mediastino, sistema nervioso central, pleura, pulmones, hígado y hueso. Sin embargo, es extremadamente rara su aparición en el corazón. Se presenta el caso de un paciente masculino de 67 años de edad, quien consulta por disnea progresiva, edema de miembros inferiores y hepatomegalia congestiva dolorosa. Se diagnóstica mediante biopsia HEE cardiaco primario. Posteriormente, se documenta recidiva tumoral, razón por la que fue evaluado por la junta médica de tumores que decidió iniciar quimioterapia (paclitaxel más doxorrubicina liposomal durante 6 ciclos). El paciente continúa en seguimiento por oncología con evidencia de enfermedad estable. El HEE cardiaco es un tumor muy raro. El tratamiento con paclitaxel más doxorrubicina es un esquema de quimioterapia que puede ser considerado en el manejo del HEE cardíaco primario avanzado o recurrente después de la cirugía cardíaca.

show abstract

“…ST includes chemotherapy, immunotherapy, radiotherapy, TACE, and targeted therapies (45). A handful of case reports and case series have discussed the use of ST, such as Olaratumab combined with doxorubicin (46), thalidomide (47), mTOR inhibitors after LT (48), and LR followed by interferon alpha-2 (49), and have acquired good results. Vascular endothelial growth factor (VEGF) inhibitors, such as Sorafenib (50, 51), Pazopanib (52), and Bevacizumab (53), were also used in the treatment of HEHE.…”

Section: Casementioning

confidence: 99%

Hepatic epithelioid hemangioendothelioma—a single-institution experience with 51 cases

Huang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

ObjectivesThe aim of the present study was to describe the experience at a single institution in the management of hepatic epithelioid hemangioendothelioma (HEHE).MethodsWe included 51 patients with histologically confirmed HEHE. We performed log-rank (Cox–Mantel) survival analyses using Kaplan–Meier methods to test differences in survival between patients in different groups. Univariate Cox regression analyses and multivariate proportional hazards regression model were carried out to identify independent prognostic factors.ResultsDifferent imaging modalities were used to diagnose HEHE with various presentations. Liver resection (LR), liver transplantation (LT), systemic treatment (ST), and surveillance had been used in our study. A significant difference was noted between the LR group and the surveillance group with respect to mean survival (p = 0.006), as was in the LR group and the ST group (p = 0.036), and in surgical approach (LR and LT) and nonsurgical approach (ST and surveillance) (p = 0.008). The mean survival between the ST group and the surveillance group was not significantly different (p = 0.851). LR (p = 0.010) and surgical approach (p = 0.014) were favorable predictors of outcome, while macrovascular invasion (MaVI) (p = 0.037), lung metastasis (p = 0.040), and surveillance (p = 0.033) were poor prognostic factors in univariate analysis. Multivariate analysis showed that LR (p = 0.010) and surgical approach (p = 0.014) were independently associated with good OS, while surveillance (p = 0.033) was independently associated with poor OS. After adjusting for confounding factors, patients in the LR group have much better OS than those in the surveillance group (p = 0.013). However, there was no significant difference in OS between the LR group and ST group (p = 0.254), as was in the ST group and the surveillance group (p = 0.857).ConclusionsThe definitive diagnosis of HEHE was dependent on histopathology, and it was not possible to make a specific diagnosis without biopsy because the radiological findings were similar to those in some hepatic malignancies. ST was not recommended for patients who were not candidates for surgical approaches, and surgical approaches should be warranted regardless of disease stage. The retrospective nature and the small size of the data limited the generalizability of the study, designing a worldwide database that contains all data about patients with HEHE independent of their therapy, which was highly recommended.

show abstract

<p>Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?</p>

Cited by 3 publications

References 38 publications

Hepatic epithelioid hemangioendothelioma: how fast does it grow and which findings could have prevented diagnostic delay?—a case report

Hepatic epithelioid hemangioendothelioma: how fast does it grow and which findings could have prevented diagnostic delay?—a case report

Hemangioendotelioma cardiaco primario recurrente: reporte de caso y revisión de la literatura

Hepatic epithelioid hemangioendothelioma—a single-institution experience with 51 cases

Contact Info

Product

Resources

About